Krystal Biotech upgraded to Buy from Neutral at Goldman Sachs
The Fly

Krystal Biotech upgraded to Buy from Neutral at Goldman Sachs

Goldman Sachs analyst Madhu Kumar upgraded Krystal Biotech to Buy from Neutral with a price target of $124, up from $79. The May 19 FDA action date for collagen 7 herpes simplex virus gene therapy drug Vyjuvek for dystrophic pidermolysis bullosa remains the key near-term event for shareholders, the analyst tells investors in a research note. The firm’s 90% probability of success and investor conversations indicate potential approval and debates around Vyjuvek are now primarily focused on the launch, says the analyst. The firm believes approval could drive further upside in Krystal shares.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on KRYS:

Related Articles
GlobeNewswireKrystal Biotech to Present at 2024 Cantor Global Healthcare Conference
TheFlyIntellia Therapeutics price target lowered to $64 from $80 at Stifel
TheFlyKrystal Biotech price target raised to $220 from $204 at Stifel
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App